Oct 31, 2019
Landmark deal secures significant discount on price of medicine to prevent TB
Peru has the highest burden of multidrug-resistant tuberculosis (MDR-TB) in Latin America. Patients with MDR-TB currently have to endure a painful two-year treatment involving as many as 20 pills a day and injectables, which can cause psychosis and hearing loss. Thanks to a new generation MDR-TB treatment regimen that is simpler, shorter and less toxic, patients are able to get cured more quickly. Unitaid is investing US$80 million to expand access to this treatment.